Top

Cancer Chemotherapy and Pharmacology

Published in:

01-06-2013 | Original Article

Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors

Authors: J. F. Deeken, B. Shimkus, A. Liem, D. Hill, J. Gurtler, E. Berghorn, L. Townes, H. Lu, O. Trifan, S. Zhang

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2013

Abstract

Purpose

Greater scrutiny is being placed on developing a full understanding of potential cardiotoxicity of therapeutic agents, especially on the potential to prolong the QTc interval which can lead to arrhythmias such as torsade de pointes and sudden death. This trial was designed to specifically evaluate the effect, if any, of cetuximab on the QTc interval in patients with advanced solid tumors.

Methods

Cetuximab was administered as an initial dose of 400 mg/m² on day 1 (week 1) followed by a maintenance dose of 250 mg/m² weekly thereafter. ECG monitoring was performed at screening, baseline (week 1 preceding dosing), and during week 1 to 5 of treatment. Cetuximab concentration-to-QTc relationship was evaluated based on cetuximab serum samples obtained at the time of each ECG measurement to allow for accurate correlation between any observed QT/QTc changes and cetuximab serum concentration.

Results

At the recommended dose (400 mg/m² on day 1 followed by 250 mg/m² weekly), cetuximab had no clinically meaningful effect on QTc interval, PR or QRS intervals, or heart rate and there was no apparent concentration-dependent effect of cetuximab on any of these electrocardiogram parameters. Safety observations in patients treated with cetuximab in this study were consistent with the agent’s known safety profile.

Conclusion

These results suggest that cetuximab can be safely administered as a single agent without risk of effect on QTc interval.

Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. JNCI 102:14–25PubMedCrossRef

Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G et al (2011) Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol/Hematol 80:369–379CrossRef

Brana I, Taberno J (2010) Cardiotoxicity. Ann Oncol 21(Suppl 7):vii173–vii179PubMedCrossRef

Yeh ETH, Bickford CL (2009) Cardiovascular complications of cancer therapy. J Am Coll Cardiol 53:2231–2247PubMedCrossRef

Mirvis DM, Goldberger AL (2005) Electrocardiography. In: Zipes DP, Libby P, Braunwald E, Bonow RO (eds) Braunwald’s heart disease: a textbook of cardiovascular medicine, 7th edn. Saunders, Philadelphia, pp 107–151

Belardinelli L, Antzelevitch C, Vos MA (2003) Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 24:619–625PubMedCrossRef

Bazett HC (1920) An analysis of the time relationship of electrocardiograms. Heart 7:353–370

Fridericia LS (1920) Die Systolendauer im Elektrokardiogramm bei normalen menschen und bei herzkranken [letter]. Acta Med Scand 53:489CrossRef

Hodges M, Salerno Q, Erlien D (1983) Bazett’s QT correction reviewed. Evidence that a linear QT correction for heart rate is better (abstract). J Am Coll Cardiol 1:694

10.

Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D (1992) An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 70:797–801PubMedCrossRef

11.

Strevel EL, Ing DJ, Siu LL (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25:3362–3371PubMedCrossRef

12.

Bagnes C, Panchuk PN, Recondo G (2010) Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Safety 5:93–96CrossRef

13.

Raschi E, Vasina V, Ursino MG, Boriani G, Martoni A, De Ponti F (2010) Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther 125:196–218PubMedCrossRef

14.

Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215–2220PubMedCrossRef

15.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Steering Committee: ICH Harmonized Tripartite Guideline: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, E14. Geneva, Switzerland, ICH 2005. Available at: http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html

16.

FDA Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs 2006. Available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129357.pdf

17.

National Cancer Institute: Cancer therapy evaluation program, Common terminology for adverse events, version 3.0 DCTD, NCI, NIH, DHHS, 2006. Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf

18.

Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311–1318PubMed

19.

Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345PubMedCrossRef

20.

Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048PubMedCrossRef

21.

Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765PubMedCrossRef

22.

Van Cutsem E, Kohne C-H, Lang I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019PubMedCrossRef

23.

Bonner JA, Harai PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 345:567–578CrossRef

24.

Burtness G, Goldwasser MA, Flood W, Mattar B, Forastiere AA (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer. An Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646–8654PubMedCrossRef

25.

Vermorkin JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127CrossRef

26.

Guidance for industry, E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, 2005. Available at http://www.fda.gov/cder/Guidance/6922fnl.pdf

27.

Garnett CE, Beasley N, Bhattaram VA et al (2007) Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 48:13–18CrossRef

28.

Fracasso PM, Howard Burris III, Arquette MA et al (2007) Pharmacodynamic rationale for dosing study of cetuximab: pharmacokinetic and a phase 1 escalating single-dose and weekly fixed-dose. Clin Cancer Res 13:986–993PubMedCrossRef

29.

Pettrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S (2012) Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 11(Suppl 1):S9–S19CrossRef

30.

Raschi E, De Ponti F (2012) Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. Intern Emerg Med 7:113–131PubMedCrossRef

31.

Albini A, Cesana E, Dontaelli F, Cammarota R, Bucci EO, Baravelli M et al (2011) Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. Futur Cardiol 7:693–704CrossRef

32.

Keating GM (2010) Panitumumab: a review of its use in metastatic colorectal cancer. Drugs 70:1059–1078PubMedCrossRef

33.

NCT01412957: A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects with Chemorefractory Wild-type KRAS Metastatic Colorectal Cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01412957?id=NCT01412957&rank=1. Accessed 12 July 2012

34.

Al-Khatib SM, Allen La Pointe NM, Kramer JM, Califf RM (2003) What clinicians should know about the QT interval. JAMA 30:2120–2127CrossRef

Title: Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors
Authors: J. F. Deeken
B. Shimkus
A. Liem
D. Hill
J. Gurtler
E. Berghorn
L. Townes
H. Lu
O. Trifan
S. Zhang
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-013-2146-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2013

Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin

Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

Bevacizumab and central nervous system (CNS) hemorrhage

Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil

A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer